{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:12:49Z","timestamp":1780495969417,"version":"3.54.1"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>\n            The Clinical and Laboratory Standards Institute (CLSI) broth microdilution method was used to evaluate the\n            <jats:italic>in vitro<\/jats:italic>\n            activities of plazomicin and comparator antimicrobial agents against 7,712 Gram-negative and 4,481 Gram-positive bacterial pathogens obtained from 2013 to 2017 from patients in Canadian hospitals as part of the CANWARD Surveillance Study. Plazomicin demonstrated potent\n            <jats:italic>in vitro<\/jats:italic>\n            activity against\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            (MIC\n            <jats:sub>90<\/jats:sub>\n            \u2264 1\u2009\u00b5g\/ml for all species tested except\n            <jats:named-content content-type=\"genus-species\">Proteus mirabilis<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">Morganella morganii<\/jats:named-content>\n            ), including aminoglycoside-nonsusceptible, extended-spectrum \u03b2-lactamase (ESBL)-positive, and multidrug-resistant (MDR) isolates.\n          <\/jats:p>","DOI":"10.1128\/aac.02068-18","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T11:42:31Z","timestamp":1540899751000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":26,"title":["<i>In Vitro<\/i>\n            Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study"],"prefix":"10.1128","volume":"63","author":[{"given":"Andrew","family":"Walkty","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Shared Health, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Shared Health, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Baxter","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Shared Health, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Zhanel","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.12.25"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00572-10"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1095180"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00556-09"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02454-16"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx239"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx261"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.11.004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.02.011"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01477-07"},{"key":"e_1_3_2_13_2","first-page":"S127","article-title":"16S rRNA methylase containing Enterobacteriaceae in the SENTRY Asia-Pacific region frequently harbour plasmid-mediated quinolone resistance and CTX-M types","volume":"2","author":"Bell JM","year":"2010","unstructured":"Bell JM, Andersson P, Jones R, Turnidge J. 2010. 16S rRNA methylase containing Enterobacteriaceae in the SENTRY Asia-Pacific region frequently harbour plasmid-mediated quinolone resistance and CTX-M types. Clin Microbiol Infect 2(Suppl):S127.","journal-title":"Clin Microbiol Infect"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.03.016"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky344"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01989-17"},{"key":"e_1_3_2_17_2","volume-title":"Plazomicin versus meropenem for complicated urinary tract infection (cUTI) and acute pyelonephritis (AP): diagnosis-specific results from the phase 3 EPIC study","author":"Cloutier DJ","year":"2017","unstructured":"Cloutier DJ, Komirenko AS, Cebrik DS, Keepers TR, Krause KM, Connolly LE, Wagenlehner FME. 2017. Plazomicin versus meropenem for complicated urinary tract infection (cUTI) and acute pyelonephritis (AP): diagnosis-specific results from the phase 3 EPIC study, abstr 1855. Abstr IDWEEK 2017, San Diego, CA."},{"key":"e_1_3_2_18_2","volume-title":"Zemdri\u2122 (plazomicin) injection, for intravenous use. Prescribing information","author":"Achaogen","year":"2018","unstructured":"Achaogen. 2018. Zemdri\u2122 (plazomicin) injection, for intravenous use. Prescribing information. Revised June. Achaogen, Inc., South San Francisco, CA."},{"key":"e_1_3_2_19_2","volume-title":"Improved outcomes with plazomicin compared with colistin in patients with bloodstream infections caused by carbapenem-resistant Enterobacteriaceae (CRE): results from the CARE study","author":"McKinnell JA","year":"2017","unstructured":"McKinnell JA, Connolly LE, Pushkin R, Jubb AM, O\u2019Keeffe B, Serio AW, Smith A, Gall J, Riddle V, Krause KM, Pogue JM. 2017. Improved outcomes with plazomicin compared with colistin in patients with bloodstream infections caused by carbapenem-resistant Enterobacteriaceae (CRE): results from the CARE study, abstr 1853. Abstr IDWEEK 2017, San Diego, CA."},{"key":"e_1_3_2_20_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M07, 11th ed. CLSI, Wayne, PA.","edition":"11"},{"key":"e_1_3_2_21_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing. Document M100, 28th ed. CLSI, Wayne, PA.","edition":"28"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00313-18"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq459"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.05.016"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02068-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02068-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:21:10Z","timestamp":1645478470000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02068-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1128\/AAC.02068-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02068-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"2018-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02068-18"}}